Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A phase 1/2 trial of Daraxonrasib, Bevacizumab, Cetuximab in colorectal cancer and pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors is a phase 1/2 interventional study registered as NCT06445062 by Revolution Medicines, Inc., with 1130 participants planned, started 2024-05-24 and due to reach its primary completion in 2027-05-15. Interventions recorded: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab. Conditions listed: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Gemcitabine.
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Revolution Medicines, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Shares Zoldonrasib, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.